ALRTF (ALR Technologies SG) Cash Conversion Cycle: 0.00 (As of Dec. 2025)


What is ALR Technologies SG Cash Conversion Cycle?

ALR Technologies SG ALRTF +16.67% Cash Conversion Cycle is 0.00 as of Dec. 2025. The stock has 3 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

ALR Technologies SG's Days Sales Outstanding for the six months ended in Dec. 2025 was 0.
ALR Technologies SG's Days Inventory for the six months ended in Dec. 2025 was 0.
ALR Technologies SG's Days Payable for the six months ended in Dec. 2025 was 0.
Therefore, ALR Technologies SG's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2025 was 0.00.


ALR Technologies SG  (OTCPK:ALRTF) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


ALR Technologies SG Cash Conversion Cycle Related Terms


ALR Technologies SG Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for ALR Technologies SG's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ALR Technologies SG Cash Conversion Cycle Chart

ALR Technologies SG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only -153,391.25 -339,450.00 -16,999.96 0.00 0.00

ALR Technologies SG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 793.17 0.00 0.00 0.00 0.00

ALRTF vs ALUR, NXL, VVOS: Cash Conversion Cycle Comparison

For the Medical Devices subindustry, ALR Technologies SG's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ALR Technologies SG Cash Conversion Cycle vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ALR Technologies SG's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where ALR Technologies SG's Cash Conversion Cycle falls into.



ALR Technologies SG Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

ALR Technologies SG's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=0+0-0
=0.00

ALR Technologies SG's Cash Conversion Cycle for the quarter that ended in Dec. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 0.00 mean?
ALR Technologies SG (ALRTF) has a Cash Conversion Cycle of 0.00 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on ALR Technologies SG and its competitors.
Is ALR Technologies SG's Cash Conversion Cycle too high?
ALR Technologies SG's current Cash Conversion Cycle is 0.00.
How does ALR Technologies SG's Cash Conversion Cycle compare to ALUR and NXL?
ALR Technologies SG's Cash Conversion Cycle of 0.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 819 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on ALR Technologies SG and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ALR Technologies SG's current Cash Conversion Cycle is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALR Technologies SG stock overvalued right now?
ALR Technologies SG (ALRTF) has a current Cash Conversion Cycle of 0.00. The current Cash Conversion Cycle is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For ALR Technologies SG (ALRTF), the current Cash Conversion Cycle is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ALR Technologies SG Business Description

Address 9 Raffles Place, No. 26-01, Republic Plaza, Singapore, SGP, 048619
ALR Technologies SG Ltd is a medical device company that focuses on commercializing its Health-e-Connect System. The company is a data management company that developed a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA-compliant Diabetes Solution product that can collect data from BGM and CGM; a patent-pending Predictive A1C algorithm to track treatment success between lab reports; and an FDA-cleared Insulin Dosing Adjustment program. Geographically, it operates in the United States and Singapore.